Your reply is nonsense.
Arkoosh has said a number of times he would pursue all viable avenues, including SFA (as for letting Norton go, that may be something he would have done). You don't want to believe this, that is your problem. You're the one who claims to never have had the time to call Arkoosh, so the inability to determine this one on your own is your fault. I'm sure you could find an hour to personally get an answer to what you've been saying is this all important issue.
Go look at my previous post, you know very well I went into detail about Arkoosh's other qualifications. You're the one who seems eager to get away from a comparison of Arkoosh's qualifications to Kemp's. I wonder why that is?
The ASE matter was certainly settled. I don't know how you can claim otherwise. It allowed trading in the U.S. How many stock options did Arkoosh get at the time and at what price? Is Kemp working for just options right now?
You keep trying to escape from the reality that Arkoosh recommended against the limited settlement. What did Kemp do, answer that question. Kemp was able to oust JJ, but as the company's legal counsel and, his firm the company's outside counsel, you're telling me he could not influence the decision to hold off on settling the ASE issues until the ASC was included. Too incredible for me to believe. As the company's legal counsel as well as director as well as the person whose firm serves as outside counsel to Naxos, I doubt very much his influence was not much greater than Arkoosh's.
If you're implying Arkoosh supported Walters in any way during that period, this is a further example of what your refusal to speak to Arkoosh does to your judgment.
I don't claim that all of Kemp's moves have been bad. One can bring up the addition of CPM as a positive accomplishment (albeit, I don't know if it was actually Kemp's accomplishment and we have yet to see how positive this addition is). That, however, does not excuse his other infirmities, including the ASE/ASC issue (which is adversely effecting Naxos to this very day), the lack of investment in this company (to the contrary, he constantly sells whatever stock he acquires), his and his firm's apparent failure to properly advise Naxos regarding its reporting requirements, continued leaks, and his inability to deal effectively with Ledoux (the most important issue IMO). Of equal significance, is whether he properly issued the release stating Ledoux has backed off of its assays. He had an opportunity to answer questions about Ledoux and the release at the AGM but, from what I've heard, arrogantly refused to do so.
|
